{
  "docId": "019dd923-5e88-73ef-bd5a-2e760724f3df",
  "docSlug": "6d3545a6c010d7cb",
  "documentTitle": "Eyepoint Goldman Sachs June 10 2025",
  "authorId": "GoldmanSachs",
  "authorName": "EyePoint Pharmaceuticals",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "equity_research",
  "sourceTypeLabel": "Equity research",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 18,
  "pageCount": 29,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "case_study",
  "function": "illustrate_case",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a split-layout with a summary/thesis on the left and specific trial results on the right.",
  "elementsJson": [
    "headline_text",
    "bullet_list",
    "paragraph"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5e88-73ef-bd5a-2e760724f3df/18",
  "deckHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df",
  "deckJsonHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df.json",
  "deckAnchorHref": "/decks/019dd923-5e88-73ef-bd5a-2e760724f3df#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Data supports DURAVYU as a Potential Treatment for DME with improvement in vision and anatomy with superior dosing intervals.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a620-c2a040bf9678",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.4,
        "y": 0.93
      },
      "kind": "disclaimer",
      "text": "DME, diabetic macular edema; BCVA, best-corrected visual acuity; CST, central subfield thickness; SAEs, serious adverse events.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b49b3387-7a2a-477b-b74a-ec71f0302e61",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.4,
        "y": 0.12
      },
      "kind": "list",
      "text": "DURAVYU 2.7mg EFFICACY: Primary endpoint achieved - extended time to first supplemental injection vs. aflibercept control; Early and sustained BCVA improvement = +7.1 letters; Early and sustained CST improvement = -76 microns",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b9948d13-3b99-4261-bf25-6d975c1e1c05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.55,
        "x": 0.4,
        "y": 0.5
      },
      "kind": "list",
      "text": "DURAVYU SAFETY RESULTS: No DURAVYU-related ocular or systemic SAEs; No cases of: Impaired vision, Endophthalmitis, Retinal vasculitis, Intraocular inflammation (IOI), Insert migration",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec097f1c-6bce-40bc-b7ca-847f212b41e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "BCVA improvement: +7.1",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd952-1d6c-779c-a620-c6e71e71fd60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.32,
        "x": 0.06,
        "y": 0.58
      },
      "kind": "title",
      "text": "Data supports DURAVYU as a Potential Treatment for DME with improvement in vision and anatomy with superior dosing intervals",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1dfef027-e427-4d4a-9e2b-30e6446f122e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.32,
        "x": 0.06,
        "y": 0.13
      },
      "kind": "title",
      "text": "VERONA: Phase 2 Clinical Trial Met Primary and Key Secondary Endpoints",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a8d138c5-0a67-4441-8c9b-4b8fe30740d2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}